IO Biotech, Inc.
IOBTQDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IO102-IO103 | Phase 3 | Melanoma | - | - |
IO102 | Phase 2 | NSCLC | - | - |
Frequently asked questions
What is in IO Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in IO Biotech, Inc.'s (IOBTQ) pipeline across Phase 3, Phase 2. Its lead program is IO102-IO103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IO Biotech, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for IO Biotech, Inc. (IOBTQ) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IOBTQ biotech catalysts?→
Add IOBTQ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IO Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.